TreatSMA at a meeting at the House of Commons

Today members of TreatSMA and their children attended a Fast Track Treatment Campaign meeting organised by Muscular Dystrophy UK at the House of Commons.

This was an opportunity for MPs to drop in to talk to representatives and people with muscle wasting conditions. There was a Q&A session which was chaired by Mary Glindon MP, Chair of the All Party Parliamentary Group for Muscular Dystrophy. Contributions were from Professor Francesco Muntoni, Director of Dubowitz Neuromuscular Centre at the UCL Institute of Child Health and Great Ormond Street Hospital, London, and Sheela Upadhyaya, Associate Director, Highly Specialised Technologies, NICE.

What came across clear today is just how much NICE is wanting SMA families to put forward their stories.  They want raw insight into life with SMA and are keen to hear what Spinraza could do for you or your child rather than hearing about the devastation SMA has caused. So we ask people to start noting what Spinraza has done done for you for you so far or what it could do for you.

The community input puts human tragedy into the content of figures and economic data. It will play a key part of the decision process. But it is up to the community to collect and present this part.

NICE must work within the framework established, which means that only HST or STA routes for appraising new treatments are available. We and the wider community understand that neither the HST nor the STA route is suitable for SMA and similar rare diseases. Sadly, there is nothing in-between. However, even as STA has been assigned to Spiraza, NICE will use the HST team to move the project further and bring in certain elements from the HST route. Furthermore, a form of Managed Access Agreement will be put in place to help the process. A MAA allows stakeholders to collect data, it allows the NHS to manage funds and it gives earlier access to treatment.

NICE said it would have been an injustice if all types were not looked at across the board, though the price for this number of people will open up challenges.

This is a big precedent and clearly shows that whilst the processes are outdated there is willingness for compromise and change. We are proud to be part of this change.

Latest Posts

  • Calling on all the community to ACT NOW to avoid losing treatments!

    Calling on all the community to ACT NOW to avoid losing treatments!

    Currently, there are two approved treatments for SMA: risdiplam and nusinersen. These treatments were initially approved temporarily under Managed Access Agreements while the NHS and NICE gathered data to assess their cost-effectiveness. Now, as these agreements come to an end, both treatments face a crucial review.

    Read more

  • NICE’s upcoming Multi Technology Assessment for Spinraza and Risdiplam

    NICE’s upcoming Multi Technology Assessment for Spinraza and Risdiplam

    SMA UK are proud to join together with Treat SMA and MDUK to bring you this webinar about NICE’s upcoming Multi Technology Assessment for Spinraza and Risdiplam. 2024 sees the end of the managed access agreements (MAAs) for the two treatments. An expert committee will gather to assess the new clinical and real-world evidence, along…

    Read more

  • Let the battle begin

    Let the battle begin

    This year the Managed Access Agreement for Spinraza and Risdiplam expires. The MAA was put in place five years ago so the pharmaceutical companies could gather more evidence to resubmit to NICE for approval on the NHS with Biogen extending their MAA by a year.

    Read more